SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT 2) MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Market is Segmented by Drug (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography

Market Snapshot

Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Middle East and North Africa
Largest Market: North America
CAGR: >11 %
Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The market for SGLT2 is worth USD 7.2 billion in 2020 and is expected to grow at a CAGR greater than 11% by 2026. The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga. The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.

Scope of the Report

The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.

By Drug
Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2016 - 2026)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
North America
United States (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Canada (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of North America (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Europe
France (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Germany (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Italy (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Spain (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
United Kingdom (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Russia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Europe (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Latin America
Mexico (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Brazil (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Latin America (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Asia-Pacific
Japan (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Korea (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
China (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
India (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Australia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Vietnam (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Malaysia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Indonesia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Philippines (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Thailand (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Asia-Pacific (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Middle-East and Africa
Saudi Arabia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Iran (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Egypt (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Oman (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Africa (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Middle-East and Africa (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Jardiance is Leading the SGLT2 Market.

Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes. Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream. Jardiance accounted for more than 30% of the sales in the global SGLT2 class of drugs in 2020. 

Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Key Trends

65% of the Market Share is Occupied by North America.

North America accounts for the highest type- 2 diabetic population. The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. Prices are comparatively high in this region. Jardiance holds 50% of the market share in the US SGLT2 market. The American Diabetes Association Standards of Care has recommended empagliflozin (the active pharmaceutical ingredient in Jardiance) as the only diabetic drug that reduces the risk of cardiovascular death in adults with Type-2 diabetes. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obesity population, which is a prominent cause of type 2 diabetes. The diabetic type 2 population in the country accounts for 95% of all the diabetic population. The sales of non-insulin drugs account for 53% of the market value of diabetic drugs in the country.

Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Growth by Region

Competitive Landscape

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is highly consolidated, with a few significant manufacturers having a global market presence. The companies strengthen their market presence by getting approval in new forms. For example, In Japan, Forxiga was also approved for adults with type 1 diabetes regardless of BMI in the year 2019.

RECENT DEVELOPMENTS

In November 2020, Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2016 - 2026)

        1. 5.1.1.1 Invokana (Canagliflozin)

        2. 5.1.1.2 Jardiance (Empagliflozin)

        3. 5.1.1.3 Farxiga/Forxiga (Dapagliflozin)

        4. 5.1.1.4 Suglat (Ipragliflozin)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2016 - 2026)

          1. 5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.1.2 Canada (Value and Volume 2016 - 2026)

          1. 5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.1.3 Rest of North America (Value and Volume 2016 - 2026)

          1. 5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2016 - 2026)

          1. 5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.2.2 Germany (Value and Volume 2016 - 2026)

          1. 5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.2.3 Italy (Value and Volume 2016 - 2026)

          1. 5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        4. 5.2.2.4 Spain (Value and Volume 2016 - 2026)

          1. 5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        5. 5.2.2.5 United Kingdom (Value and Volume 2016 - 2026)

          1. 5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        6. 5.2.2.6 Russia (Value and Volume 2016 - 2026)

          1. 5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        7. 5.2.2.7 Rest of Europe (Value and Volume 2016 - 2026)

          1. 5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2016 - 2026)

          1. 5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.3.2 Brazil (Value and Volume 2016 - 2026)

          1. 5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2016 - 2026)

          1. 5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2016 - 2026)

          1. 5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.4.2 South Korea (Value and Volume 2016 - 2026)

          1. 5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.4.3 China (Value and Volume 2016 - 2026)

          1. 5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        4. 5.2.4.4 India (Value and Volume 2016 - 2026)

          1. 5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        5. 5.2.4.5 Australia (Value and Volume 2016 - 2026)

          1. 5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        6. 5.2.4.6 Vietnam (Value and Volume 2016 - 2026)

          1. 5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        7. 5.2.4.7 Malaysia (Value and Volume 2016 - 2026)

          1. 5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        8. 5.2.4.8 Indonesia (Value and Volume 2016 - 2026)

          1. 5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        9. 5.2.4.9 Philippines (Value and Volume 2016 - 2026)

          1. 5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        10. 5.2.4.10 Thailand (Value and Volume 2016 - 2026)

          1. 5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2016 - 2026)

          1. 5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2016 - 2026)

          1. 5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.5.2 Iran (Value and Volume 2016 - 2026)

          1. 5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.5.3 Egypt (Value and Volume 2016 - 2026)

          1. 5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        4. 5.2.5.4 Oman (Value and Volume 2016 - 2026)

          1. 5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        5. 5.2.5.5 South Africa (Value and Volume 2016 - 2026)

          1. 5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2016 - 2026)

          1. 5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2026)

    2. 6.2 Type-2 Diabetes Population (2016 - 2026)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Eli Lilly

      2. 7.1.2 Janssen Pharmaceuticals

      3. 7.1.3 Bristol Myers Squibb

      4. 7.1.4 Boehringer Ingelheim

      5. 7.1.5 AstraZeneca

      6. 7.1.6 Astellas

    2. 7.2 MARKET SHARE ANALYSIS

      1. 7.2.1 Eli Lilly

      2. 7.2.2 Janssen Pharmaceuticals

      3. 7.2.3 Astellas

      4. 7.2.4 Boehringer Ingelheim

      5. 7.2.5 AstraZeneca

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market market is studied from 2016 - 2027.

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is growing at a CAGR of >11% over the next 5 years.

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is valued at 7 Billion USD in 2016.

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is valued at 12 Billion USD in 2027.

Middle East and North Africa is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, Astellas are the major companies operating in Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!